79421-43-5Relevant articles and documents
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 001550; 001551; 001715; 001716, (2021/01/22)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203
Kang, Sunhee,Kim, Young Mi,Kim, Ryang Yeo,Seo, Min Jung,No, Zaesung,Nam, Kiyean,Kim, Sanghee,Kim, Jaeseung
, p. 807 - 815 (2016/10/24)
The anti-tubercular activity of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl)imidazo [1,2-a]pyridine-3-carboxamide (Q203) is modified by varying its side chain. In this study, we synthesized Q203 analogues with different side
New oxadiazole derivatives
-
Page/Page column 24, (2011/10/10)
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: and its use in the treatment of diseases which are susceptible to improvement by sphingosine-1-phosphate (S1P1) receptor agonists.